Fig. 6From: Cost-effectiveness in unstable economies: the case of sacubitril/valsartan in heart failure with reduced ejection fraction in ArgentinaProbability for sacubitril/valsartan of being accepted as cost-effective for a private payer. Value of ceiling ratio represents the range of cost-effectiveness thresholds. The curve represents the probability for sacubitril/valsartan of being Accepted as a cost-effective option, considering a range of cost-effectiveness thresholds. At (1 GDP per capita of 520,405.79 ARS the probability is 92%Back to article page